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Summary
Objective: Chitosaneglycerol phosphate (chitosan-GP) is a unique polymer solution that is mixed with whole blood and solidiﬁed over micro-
fractured or drilled articular cartilage defects in order to elicit a more hyaline repair cartilage. For clinical ease-of-use, a faster in situ solidiﬁ-
cation is preferred. Therefore, we investigated the mechanisms underlying chitosaneGP/blood implant solidiﬁcation.
Methods: In vitro solidiﬁcation of chitosaneGP/blood mixtures, with or without added clotting factors, was evaluated by thromboelastography.
Serum was analyzed for the onset of thrombin, platelet, and FXIII activation. In vivo solidiﬁcation of chitosaneGP/blood mixtures, with and
without clotting factors, was evaluated in microdrilled cartilage defects of adult rabbits (N¼ 41 defects).
Results: ChitosaneGP/blood clots solidiﬁed in an atypical biphasic manner, with higher initial viscosity and minor platelet activation followed
by the development of clot tensile strength concomitant with thrombin generation, burst platelet and FXIII activation. Whole blood and chito-
saneGP/blood clots developed a similar ﬁnal clot tensile strength, while polymereblood clots showed a unique, sustained platelet factor
release and greater resistance to lysis by tissue plasminogen activator. Thrombin, tissue factor (TF), and recombinant human activated factor
VII (rhFVIIa) accelerated chitosaneGP/blood solidiﬁcation in vitro (P< 0.05). Pre-application of thrombin or rhFVIIaþ TF to the surface of
drilled cartilage defects accelerated implant solidiﬁcation in vivo (P< 0.05).
Conclusions: ChitosaneGP/blood implants solidify through coagulation mechanisms involving thrombin generation, platelet activation and
ﬁbrin polymerization, leading to a dual ﬁbrinepolysaccharide clot scaffold that resists lysis and is physically more stable than normal blood
clots. Clotting factors have the potential to enhance the practical use, the residency, and therapeutic activity of polymereblood implants.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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A current aim and major challenge in orthopedic practice is
to regenerate durable cartilage in focal articular lesions1e3.
Cartilage is avascular and when damaged fails to bleed and
therefore lacks an efﬁcient wound repair response. To stim-
ulate a natural wound response, surgeons have developed
techniques like bone marrow stimulation involving drilling or
microfracture in the base of the de´brided cartilage lesion to
induce subchondral bleeding and generate conduits to per-
mit bone marrow stem cell migration into the cartilage
lesion3e6. However in skeletally mature human patients
and animal models, these surgical techniques principally
result in the formation of a repair tissue predominantly com-
posed of ﬁbrous tissue or ﬁbrocartilage, tissue types with
weak biomechanical properties compared to hyaline articu-
lar cartilage2,5,7e13. Treatments that improve the volume,*Address correspondence and reprint requests to: Caroline
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Polytechnique Montreal, 2900 Boul. Edouard Montpetit, Montreal,
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953integration, and hyaline quality of marrow-derived repair tis-
sue are therefore the focus of intense research.
Bleeding and the formation of a blood clot are initiating
events of microfracture therapy6, however the clot is best
retained in the bone defect and not on the cartilage surfa-
ce14e16. To improve clot retention in the cartilage lesion fol-
lowing microfracture and drilling, we previously developed
a scaffold-stabilized blood clot using chitosan, a cationic,
adhesive and biocompatible polysaccharide. Homogenous
mixtures of autologous whole blood and solutions of
chitosaneglycerol phosphate (chitosaneGP) solidify to
form a clot with morphologically normal erythrocytes and
a structurally stable ﬁbrous network with chitosan and ﬁbrin
ﬁbers17,18. Hybrid chitosan clots resist platelet-mediated
clot retraction, and remain voluminous, ﬁrm and elastic17.
The formation of a chitosaneGP/blood clot in marrow-stim-
ulated cartilage defects in sheep and rabbit improved the
quantity, hyaline quality and integration of repair cartilage
with porous subchondral bone compared to repair tissue
formed by microfracture or drilling alone17,19. Hybrid clots
were shown to promote hyaline repair by attracting neutro-
phils, marrow-derived repair cells, and by stimulating tran-
sient angiogenesis and bone remodeling15.
954 C. Marchand et al.: ChitosaneGP/blood solidiﬁcation mechanismsMixture of liquid chitosaneGP into whole blood generates
a hybrid clot implant that forms within 10e15 min after
depositing in large animal or patient microfracture de-
fects19,20. A more rapid implant solidiﬁcation could facilitate
treatment of larger defects with curved surfaces and uncon-
ﬁned borders, and also reduce the length of the cartilage
repair procedure. Indeed, for clinician ease-of-use, a faster
and controlled in situ solidiﬁcation is preferred; however
solidiﬁcation mechanisms are incompletely understood.
Many studies previously demonstrated that acidic chitosan
solutions and solid chitosan particles are thrombogenic,
through mechanisms involving red blood cell (RBC) agglu-
tination, and platelet activation, without direct activation of
the clotting cascade17,21e23. By comparison, little is under-
stood concerning the hemostatic properties of isotonic
and near-neutral pH chitosaneGP solutions.
The ﬁrst aim of the current study was to elucidate solidi-
ﬁcation mechanisms of chitosaneGP/blood in vitro, using
a Thromboelastograph (TEG), an instrument that mea-
sures clotting time and clot tensile strength. We tested the
hypothesis that chitosaneGP/blood solidiﬁcation is throm-
bin-dependent, and furthermore implicates platelet and Fac-
tor XIII activation. The second aim of this study was to
develop novel methods to accelerate in situ solidiﬁcation
in an in vivo animal cartilage repair model. We therefore
tested the hypothesis that in vivo solidiﬁcation of
chitosaneGP/blood mixtures in microdrilled articular carti-
lage defects can be accelerated using clotting factors in-
cluding thrombin (IIa), tissue factor (TF) and recombinant
human factor VIIa (rhFVIIa). Tissue factor is a transmem-
brane receptor constitutively expressed in mainly extravas-
cular tissues. TF binding with trace amounts of activated
FVIIa that are present in plasma24 triggers the extrinsic
clotting cascade and thrombin generation. In our in vivo
experiments, we used a recombinant TFephospholipid
preparation at concentrations previously employed in
clinical applications for maxillary bone grafts25, rhFVIIa at
concentrations around threefold greater than the target
plasma levels for clinical applications (w2 mg/mL)26, and
thrombin concentrations within the low range used in stan-
dard ﬁbrin glue27. Our choice of these particular factors was
thus based on their known ability to promote repair pro-
cesses, as well as their current use in other clinical contexts
which could help translate their use in cartilage repair
strategies involving polymereblood implants.Materials and methodsMATERIALSMedical-grade sterile solutions of chitosan (2.05%w/v, 80% degree of
deacetylation, DDA, 1200–2000 mPa s., pH 5.6, <100 EU/mL endotoxins
units and <5 ppm heavy metal content) and 500 mM disodium b-glycerol
phosphate/50 mM HCl pH 7.1 (GP) were provided by Bio Syntech Inc
(Laval, QC, Canada). ChitosaneGP solutions were formed aseptically by
combining 1.2 mL chitosaneHCl with 0.3 mL GP. Rhodamine B-isothiocya-
nate (RITC)echitosan 0.5%mol/mol RITC/chitosan (80.5% DDA, Mn
144 kDa, polydispersity (Mw/Mn) 1.3) was prepared as 5 mg/mL ﬁlter-sterile
solutions as previously described28. Calibrated viscosity standards
(N62000, N1000, S60) were from Canon Instrument Company (State Col-
lege, PA, USA) and silicon oil (pure silicone ﬂuid) was from Clearco Prod-
ucts (Bensalem, PA, USA). Other reagents included sterile recombinant
human Factor VIIa (NovoNordisk, Copenhagen, Denmark), tissue culture-
grade puriﬁed human thrombin and benzamidine (SigmaeAldrich, Oakville,
ON, Canada), TF (Innovin) and thrombineantithrombin (TAT) enzyme-
linked immunosorbent assay (ELISA) kits (Dade Behring, Mississauga,
ON, Canada), and pooled normal plasma for TAT ELISA sample dilution
(Precision Biologic, Dartmouth, Nova Scotia, Canada), afﬁnity-puriﬁed
goat anti-human platelet factor 4 (PF4) antibody (R&D Systems, Cedarlane,
Burlington, ON, Canada), sheep anti-human A and B subunit of Factor XIII
(FXIII) antibody and Phe-Pro-Arg- chloromethylketone, a thrombin proteaseinhibitor (FPR-ck), puriﬁed human PF4 and human FXIII (Haematologic
Technologies, Essex Junction, VT, USA), donkey anti-goat-horseradish per-
oxidase (HRP) and donkey anti-sheep-HRP (Jackson Immunology, Mon-
treal, QC, Canada), chemiluminescence substrate kit (Lumi-light, Roche
Diagnostics, QC, Canada), and Hyperﬁlm ECL (Amersham Biosciences,
GE Health, ON, Canada). Recombinant tissue plasminogen activator [tPA
1 mg/mL, diluted to 2 mg/mL in phosphate-buffered saline (PBS) with
4%w/v bovine serum albumin (BSA)] was from Hoffmann-La Roche (NJ,
USA). Ringer’s lactated saline (RLS) buffer (Baxter) was purchased from
Lavigne & Dufort (Montreal, QC, Canada).CLOTTING FACTOR PREPARATION FOR IN VITRO AND
IN VIVO EXPERIMENTSFactor rhFVIIa was reconstituted with sterile water for injection from
Abbott (QC, Canada) at 500 mg/mL. Puriﬁed human IIa lyophilized powder
containing 0.15 M sodium chloride and 0.05 M sodium citrate buffer at pH
6.5 was reconstituted with sterile water for injection at 100 U/mL. Innovin
or recombinant TF containing phospholipids was freshly reconstituted with
2 mL sterile water for injection, to give 5 nM TF according to a recombinant
TF standard curve (S. Butenas, personal communication)29. For in vitro TEG
experiments, clotting factors were diluted with RLS before loading in the TEG
cups.COAGULATION ANALYSES BY THROMBOELASTOGRAPHY,
ELISA AND WESTERN BLOTClot tensile strength was evaluated for up to 180 min with four Thromboe-
lastograph (TEG) (5000 series TEG analyzer Software Version 3, Haemo-
scope, Niles, IL, USA) instruments in tandem, a set-up permitting the
simultaneous analysis of eight samples30. Venous peripheral whole blood
was drawn from healthy non-fasting consented donors (three males and
eight females, 29e47 years old, with one male and two females studied
twice), according to institutional ethics approved protocols. A ﬁrst blood
draw was used to generate chitosaneGP/blood mixtures, and a second
blood draw from the same donor was performed within 3 h to analyze un-
modiﬁed whole blood. Blood was mixed with chitosaneGP at a 3:1 v/v ratio
by vigorous shaking for 10 s in glass mixing vials containing six sterile surgi-
cal stainless steel mixing beads (0.39 g each, Salem Specialty Ball Co., Can-
ton, CT) as described17. Unmodiﬁed whole blood was transferred to sterile
borosilicate mixing vials to control for exposure to glass prior to transferring
into TEG reaction cups. TEG plastic reaction cups (made of Cyrolite G20)
were pre-loaded with 40 mL of either tPA (2 mg/mL in PBS with 4%w/v
BSA), or clotting factor diluted in RLS to give the following target concentra-
tions after adding 320 mL sample: 0.08e10 U/mL IIa; 5 mg/mL rhFVIIa;
0.7e278 pM TF; and rhFVIIaþ TF (5 mg/mL rhFVIIaþ 0.7 pM TF). Clot
tensile strength was recorded manually as the amplitude (the distance in
mm on the y-axis between the two traces). At set time intervals, the whole
reaction cup was transferred to ice cold quench buffer (20 mM 4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid (HEPES), 150 mM NaCl, 50 mM eth-
ylenediaminetetraacetic acid (EDTA), 10 mM benzamidine, 33 mM FPR-ck,
pH 7.4) at a 1:9 ratio of blood:quench buffer, vortexed for 10 s, cleared by
a double centrifugation (2500g, 15 min, 4C) and kept as aliquots at
80C until analyzed for thrombin generation by TAT ELISA30, or by
Western blot for platelet activation by appearance of serum PF431 and for ac-
tivation of FXIII as determined by cleavage of FXIII A subunit32. The
equivalent of 4 mL serum, also adjusted for dilution of blood by chitosaneGP,
was loaded into each well of a 17.5% acrylamide non-reducing sodium do-
decyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for PF4 and
2 mL serum on a 10% acrylamide SDS-PAGE reducing gel for the A and B
subunits of FXIII. Proteins were transferred to polyvinylidene ﬂuoride
(PVDF) membrane, blocked for 1 h with 5% non-fat milk powder in 50 mM
Tris, 150 mM NaCl, 0.1% Tween-20 pH 7.4 (TBST) at 50C, and probed
with goat anti-PF4 (0.2 mg/mL) then 1:10,000 diluted afﬁnity-puriﬁed donkey
anti-goat-HRP (0.08 mg/mL) or Sheep anti-human A and B subunits of FXIII
antibody (9.8 mg/mL) and donkey anti-sheep-HRP (0.08 mg/mL), followed by
chemiluminescence (Lumi-Light). Puriﬁed proteins were used as positive
controls for PF4 (20 ng/well) and FXIII (0.22 mg/well).IN VIVO ARTICULAR CARTILAGE REPAIR MODELAll animal experimentation was carried out with protocols approved by
the University of Montreal Animal Division, using skeletally mature New
Zealand White rabbits (N¼ 33 rabbits, 16 males, 17 females, >8 months
randomly assigned to different groups; 8 out of these 33 rabbits received
bilateral knee implants for a total of N¼ 41 unilateral or bilateral defects
treated with implant, see Table I). Rabbits were anesthetized with an intra-
muscular injection of ketamineexylazineebuprenorphine cocktail then
placed under 3% isoﬂurane/8% oxygen gas anesthesia. They were sub-
jected to small knee arthrotomies in order to create bilateral 3.5 4 mm
Table I
Experimental design: in vivo solidification time without and with
clotting factor
Treatment
group
Number
of defects
Clotting
factor
Technique used
to apply clotting factor
1 9 None e
2 4 rhFVIIa* Pre-mix with blood
3 5 rhFVIIay þ TFz Pre-load on defect,
w60 s delay
4 19x IIak Pre-load on defect,
w60 s delay
5 4 IIa{ Pre-load on defect,
10 s delay
*10 mg/mL (200 nM).
y5 mg/mL (100 nM).
z4.75 nM.
xN¼ 9, chitosaneGP/blood, N¼ 10, RITCechitosaneGP/blood.
k15 or 45 U/mL.
{45 U/mL.
955Osteoarthritis and Cartilage Vol. 17, No. 7trochlear defects debrided into the calciﬁed layer17. All defects were
pierced with microdrill holes (either two distal 0.9 mm drill holes and six
proximal 0.5 mm drill holes, or four 0.9 mm drill holes) with constant irriga-
tion of cold sterile RLS buffer to keep cartilage humid as previously
described15,17. Fresh non-activated autologous rabbit blood was drawn
from the central ear artery and mixed at a 3:1 v/v ratio with chitosaneGP.
For some implants, 500 mL of chitosaneGP was further combined with
100 mL RITCechitosan prior to mixing with 1.5 mL blood (see Table I,
treatment group 4). Control chitosaneGP/blood implants were delivered
from a 1 cc syringe and 20 gauge needle as one hanging drop without clot-
ting factor. In some defects, rhFVIIa was mixed into whole blood to obtain
10 mg/mL rhFVIIa (200 nM) prior to combining with chitosaneGP. In other
defects, 3 mL of concentrated clotting factor was pipetted on the defect
surface w60 s prior to liquid implant, either IIa (15 or 45 U/mL, for a target
ﬁnal concentration of 2 or 6 U/mL, respectively) or rhFVIIaþ TF [5 mg/mL
rhFVIIa and 4.75 nM TF] (see Table I). Finally, in four defects, thrombin
(45 U/mL) was ‘‘co-delivered’’ by pipetting 3 mL of on the defect surface
within 10 s of applying chitosaneGP/blood implant. In situ solidiﬁcation
time of the hybrid clot implants was noted for each implant according toTime (minutes)
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Fig. 1. Clot formation monitored by TEG showed that chitosaneGP/blo
clot tensile strength compared to whole blood. Representative TEG tra
chitosaneGP/blood mixture (B), without and with tPA (as indicated). (C) C
blood and chitosaneGPthe animal surgeon’s observations. After re-positioning the patella, knees
were closed in sutured layers.STATISTICAL ANALYSISStatistica (version 6.1, StatSoft, Tulsa, OK, USA) software was used for
multivariate correlation analysis to test TAT as a predictor of clot tensile
strength, and the non-parametric KruskaleWallis test to evaluate the effect
of clotting factor on in vivo implant solidiﬁcation time. The Student t-test
was used to determine the effect of chitosaneGP on maximum amplitude,
of added clotting factors on clotting time and clot tensile strength at 5 and
15 min. P< 0.05 was considered to be signiﬁcant.
ResultsBIPHASIC SOLIDIFICATION OF CHITOSANeGP/BLOOD
MIXTURESUnmodiﬁed whole blood coagulated in the plastic TEG sam-
ple cup around 15 min after sample deposition [Fig. 1(A)]. By
contrast, chitosaneGP/blood solidiﬁed in an atypical biphasic
manner, with a rapid and stable increase in viscosity that at
5 min was signiﬁcantly higher than whole blood [P< 0.001,
1.1 vs 0.2 mm, Fig. 1(B) and (C)]. The polymereblood initial
amplitude was also w3 greater than that of the viscous
chitosan solution prior to mixing with GP and blood, and
5 greater than chitosaneGP mixed with water instead of
blood (Table II). These data demonstrated that the rapid
thickening of chitosaneGP/blood mixtures was due to poly-
mereblood interactions. ChitosaneGP/blood mixtures had
an average clotting time of 21 min, and fully solidiﬁed over an
average 66 min period, while unmodiﬁed whole blood took
an average 43 min to reach peak clot strength [time to maxi-
mumamplitude, TMA, Fig. 1(C)]. The peak clot tensile strength
was similar for whole blood and chitosaneGP/blood [55.2 vs
51.8 mm, Fig. 1(C)]. Addition of tPA at 10-fold higher concen-
tration over normal plasma levels33,34 completely dissolved
whole blood clots after 2 h [Fig. 1(A) and (C)], whileTime (minutes)
5 4515 3525 55 65 75 85 95 105115125
B
hole Blood Chitosan-GP/blood
0.2 ± 0.1 mm 1.1 ± 0.4 mm *** 
.2 ± 5.7 mm 51.8 ± 6.4 mm 
0.7 ± 0.6 mm 11.6 ± 7.7 mm * 
.3 ± 4.8 min 21.4 ± 15.2 min
 ± 6 min 66 ± 15 min * 
etween the upper and lower TEG trace.
+tPA
10 mm
od has higher initial viscosity, delayed solidiﬁcation, and similar
ce from a non-fasting healthy subject of whole blood (A) and of
omparative development of clot tensile strength over time in whole
/blood (N¼ 5e12).
Table II
TEG amplitude of viscosity standards and chitosan solutions
Viscosity (mPa.s)* Amplitude (mm)y
Viscosity standard
N62000 198,700 27.0
Silicone oil 100,000 28.0
N1000 1998 0.4
S60 104 0.2
Chitosan solutions
2% w/v chitosaneHCl 1849 0.4
ChitosaneGP/water N/A 0.2
N/A: not available.
*At 25C.
yAt 37C.
956 C. Marchand et al.: ChitosaneGP/blood solidiﬁcation mechanismschitosaneGP/blood clots resisted complete lysis by tPA at the
same concentration [P< 0.05, Fig. 1(B)].THROMBIN, PLATELETS AND FXIII ARE ACTIVATED DURING
CHITOSANeGP/BLOOD SOLIDIFICATIONWhole blood and chitosaneGP/blood solidiﬁcation was par-
alleled by the same sequential order of clotting events, starting
with thrombin generation at around 15 min followed by burst
platelet activation (PF4) (Fig. 2). Western blot analysis of
FXIIIA and B subunits revealed a modest depletion of the A0
25
50
75
0
20
40
60
0 10 20 30 40 50 60 70 80
TEG trace
TAT
0 5 15 20 30 40 50 75
PF47.3
kDa
93
Time (minutes)
FXIII
FXIII
A
A
m
p
l
i
t
u
d
e
 
(
m
m
)
T
A
T
 
(
µ
g
/
m
L
)
T
A
T
 
(
µ
g
/
m
L
)
Amplitude (mm)
C
R2 = 0.93 
p < 0.00001
70
60
50
40
30
20
10
0
0 10 20 30 40 50 60 70
Time (minutes)
Fig. 2. Solidiﬁcation of hybrid clots is paralleled by thrombin generation, p
amplitude (TEG trace, black line, left y-axis) was superposed with TAT g
blood (A, N¼ 3) and chitosaneGP/blood (B, N¼ 4). Data are given as the
from TEG experiment showed Factor XIII activation as monitored by prote
relative to the B subunit (middle panels, 50 minþ), and platelet activation
D). Linear regression analysis between TAT generation and clot tensile
donors) and chitosaneGP/blood msubunit relative to B, immediately prior to peak clot tensile
strength, suggesting that proteolytic activation in the A subunit
by thrombin had occurred [Fig. 2(B)]. ChitosaneGP/blood
mixtures demonstrated a unique,minor platelet activation start-
ing at 5 min, coinciding with the ﬁrst phase of increased
polymereblood viscosity [see PF4, Fig. 2(B)]. Activation of
platelets at these low levels was most probably not triggered
by thrombin generation, since TAT was only detected after
a 15 min delay in chitosaneblood mixtures. TAT and PF4
levels were sustained in chitosaneGP/blood mixtures up to
75 min [Fig. 2(B)], while both TAT and PF4 levels declined in
parallel in whole blood clot serum after peak clot tensile
strength was achieved [Fig. 2(A)]. By multivariate correlation
analysis, thrombin generationwas a highly signiﬁcant predictor
of clot tensile strength for whole blood [P< 0.00001, Fig. 2(C)]
and chitosaneGP/blood [P< 0.00001, Fig. 2(D)]. These data
demonstrated that chitosaneGP/blood mixtures, like whole
blood, solidiﬁed through a thrombin-dependent mechanism.CLOTTING FACTORS RAPIDLY INCREASE
CHITOSANeGP/BLOOD CLOT TENSILE STRENGTHAddition of a variety of clotting factors (thrombin, TF,
rhFVIIa, or rhFVIIaþ TF) to the in vitro TEG sample cup prior
to addition of whole unmodiﬁed blood and chitosane
GP/blood resulted in a striking decrease in clotting time
(P< 0.05, except for 0.08 U/mL IIa where P¼ 0.3)0
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Fig. 3. Clotting factors accelerate in vitro solidiﬁcation of chitosaneGP/blood. Whole blood (A, C, E) and chitosaneGP/blood (B, D, F) were
evaluated by TEG with and without clotting factors as indicated. Panels A and B show representative TEG tracings of whole blood (A, dashed
line) and chitosaneGP/blood (B, dashed line), and parallel samples with IIa (2 U/mL), rhFVIIa (5 mg/mL), or TF (0.7 pM). The effect of clotting
factors on average clotting time (C and D) and average amplitude after 5 and 15 min (E and F) from N¼ 3 to 6 different human subjects was
analyzed for whole blood (C and E) and chitosaneGP/blood (D and F). Conditions: (0) no clotting factor added, (1) 0.08 U/mL IIa, (2) 0.4 U/mL
IIa, (3) 2 U/mL IIa, (4) 10 U/mL IIa, (5) 5 mg/mL rhFVIIa, (6) 0.7 pM TF, (7) 7.0 pM TF, (8) 278 pM TF, (9) 5 mg/mL rhFVIIaþ 0.7 pM TF.
*P< 0.05, #P< 0.01, and þP< 0.005, with respect to sample with no clotting factor.
957Osteoarthritis and Cartilage Vol. 17, No. 7[Fig. 3(A) and (B)]. The same concentration of clotting factor
had a similar ability to shorten the clotting time of unmodiﬁed
blood and chitosaneGP/blood [Fig. 3(C) and (D)]. However
the tensile strength of chitosaneGP/blood mixtures was
slower to develop than whole blood [compare 5 vs 15 min.,
Fig. 3(E) and (F)]. Tissue factor, with or without rhVIIa, in-
duced the most rapid solidiﬁcation of chitosaneGP/blood
clots [Fig. 3(F)]. Altogether, these data showed that exposure
of liquid chitosaneGP/blood mixtures to a small volume of
concentrated clotting factor could accelerate solidiﬁcation in
vitro. When thrombin was homogeneously mixed into
chitosaneGP prior to adding blood, however, the thrombine
polymereblood mixture rapidly solidiﬁed in the mixing vial
(unpublished observations). This indicated that clotting factorshould be pre-applied or co-applied to cartilage defects to
accelerate in vivo solidiﬁcation.CLOTTING FACTORS SHORTEN IN SITU CHITOSANeGP/BLOOD
IMPLANT SOLIDIFICATION TIMEIn microdrilled full-thickness cartilage defects in rabbit
trochlea [Fig. 4(A)], chitosaneGP/blood mixtures solidiﬁed
in situ with a delay of 5.0 min [Fig. 4(C), condition 1]. The
implant was conﬁrmed as solidiﬁed when it no longer ran
off the tilted defect or was no longer liquid when probed
with a blunt instrument. The time lapse between defect cre-
ation and implant loading was between 5 and 10 min, which
could theoretically lead to variability in microdrill hole
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Fig. 4. Effect of added clotting factor and delivery method on in situ solidiﬁcation time of chitosaneGP/blood implant. Trochlear cartilage defect
with microdrill holes in rabbit knee before (A) and after (B) chitosaneGP/blood implant deposition with clotting factor. (C) In situ solidiﬁcation
time of chitosaneGP/blood with various clotting factor treatments (see Table I for number of defects per treatment group): (1) no clotting factor,
(2) rhFVIIa pre-mixed with whole blood, (3) rhFVIIaþ TF deposited on defect surface w60 s prior to implant, (4) IIa deposited on defect sur-
face w60 s prior to implant, (5) IIa deposited on defect surface 10 s prior to implant. *P< 0.05 with respect to implant with no clotting factor.
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correlation was found between delay in application and in
situ solidiﬁcation time without added clotting factors (data
not shown). This suggested that delayed in situ solidiﬁca-
tion was most probably due to a variable delay in clot acti-
vation in chitosaneGP/blood mixtures, and in some cases
due to a low level of bleeding from subchondral bone.
With the aim of improving the rate of in situ solidiﬁcation,
two methods were used to combine clotting factors with
chitosaneGP/blood: (1) rhVIIa was mixed into whole blood
prior to combining with chitosaneGP, (2) 3 mL of clotting
factor (thrombin or rhVIIaþ TF) was ‘‘painted’’ on the drilled
defect prior to loading a drop of liquid chitosaneGP/blood
[Fig. 4(B) and (C), Table I]. Addition of rhFVIIa to
chitosaneGP/blood mixtures prior to delivery slightly dimin-
ished in situ solidiﬁcation time to 3.75 min, but the effect
was not signiﬁcant [Fig. 4(C), condition 2]. Painting of the
defect surface with rhFVIIaþ TF w60 s prior to delivery of
chitosaneGP/blood generated the most rapid in situ-solidi-
fying implants, 1.5 min [P¼ 0.013, Fig. 4(C), condition 3].
Painting of the defect surface with thrombin w60 s prior to
delivering the implant slightly shortened the average in
situ solidiﬁcation time to 3.5 min, but this effect was not sig-
niﬁcant [Fig. 4(C), condition 4]. By comparison, application
of thrombin only 10 s prior to delivering the implant signiﬁ-
cantly reduced in situ solidiﬁcation time from 5.0 to
2.0 min [P¼ 0.021, Fig. 4(C), condition 5].
DiscussionCHITOSANeGP/BLOOD CLOTS SOLIDIFY IN A BIPHASIC
MANNER INVOLVING POLYMEReBLOOD INTERACTION
FOLLOWED BY FIBRIN POLYMERIZATIONOur study has further elucidated the solidiﬁcation mecha-
nisms of a neutral chitosaneGP/blood mixture, whichgenerates a cytocompatible implant used for cartilage
repair17e19. ChitosaneGP/blood mixtures exhibited an
increased initial viscosity by thrombin-independent mecha-
nisms as no signiﬁcant amount of TAT was detected until
15 min after increased viscosity was observed. Higher
viscosity of bloodepolymer mixtures could be related to
chitosan precipitation or gelation at blood pH which is above
the chitosan pKa35, to early platelet activation, or to the
agglutination of RBCs by chitosan, which has also been
previously observed by ourselves and others17,21e23. Chito-
saneGP solutions were therefore pro-coagulant in that they
generated rapid and low-level platelet activation of the
mixture. The latter observation is in agreement with previ-
ous reports showing that puriﬁed platelets can bind to chitin,
to chitosan, and to ﬁbrinogen adsorbed onto chitosan via
GPIIb/IIIa integrin receptors36,37. Since tPA only partly
depressed chitosaneGP/blood clot tensile strength, this
demonstrated that both ﬁbrin and chitosan each contributed
to the tensile mechanical properties of the hybrid clot.
ChitosaneGP/blood clot resistance to tPA provides direct
evidence that incorporation of chitosan into whole blood
gives rise to a dual ﬁbrinepolysaccharide clot scaffold that
is physically more stable than whole blood clots. Therefore
hybrid blood clot implants have the potential to sustain the
ensuing wound repair response compared to normal whole
blood clots.
Platelet activation is known to support the intrinsic clotting
cascade38,39, however early and minor platelet activation
induced by chitosaneGP was insufﬁcient to accelerate
thrombin generation. The more gradual solidiﬁcation of
chitosaneGP/blood relative to whole blood could be related
to the 25% dilution of whole blood components, which
depresses ﬁbrinogen concentration40, to binding of chitosan
with ﬁbrinogen41, to activation of platelets without aggrega-
tion in the chitosaneGP/blood mixture, or to slower diffusion
959Osteoarthritis and Cartilage Vol. 17, No. 7of clotting factors, to their substrate. However it should be
noted that the TEG sample cup is made of a non-clot-
activating plastic material that does not reﬂect in vivo condi-
tions, where chitosaneGP/blood implant interacts with
components present in the de´brided cartilage surface
such as tissue factor, collagens and extravascular blood
from the drilled subchondral bone.CLOTTING FACTORS DECREASED CLOTTING TIME OF
CHITOSANeGP/BLOOD IN VITRO AND IN VIVOAll of the clotting factors tested reduced the in vitro clot-
ting time of chitosaneGP/blood, and of unmodiﬁed whole
blood, similar to what is routinely observed using TF to in-
duce in vitro coagulation of minimally modiﬁed blood and
anti-coagulated whole blood31,42. Since TF alone induced
the most rapid solidiﬁcation of chitosaneGP/blood, this sug-
gests that plasma FVII/FVIIa present in the polymereblood
mixtures was capable of rapidly complexing with TF. Rapid
coagulation of chitosaneGP/blood in the presence of TF is
therefore highly compatible with the natural mechanisms in
place to ensure hemostasis of extravascular blood.
Pre-application of rhFVIIaþ TF and thrombin in vivo to
the defect surface reduced the in situ solidiﬁcation time to
1.5 and 2 min, respectively, which represents an important
advance towards improving the clinical ease-of-use of chito-
saneGP/blood implants. Our data suggest that pre-applied
clotting factors induced a more rapid clot activation of the
implant, and a more rapid hemostasis of the bleeding drill
holes, thus contributing to a faster and more reproducible
in situ implant solidiﬁcation time. Even though instant
solidiﬁcation of the implant may be preferred, whole blood
coagulation which drives implant solidiﬁcation is known to
require a lag phase during which cellular and enzymatic
events need to take place before ﬁbrin polymerization can
begin25,32.
We are aware that our evaluation of in situ solidiﬁcation
time by the surgeon’s observations is somewhat subjective.
Even so, our methodology was sufﬁcient to demonstrate
that it is important to minimize the delay between delivery
of thrombin and implant. Given the naturally high concentra-
tion of antithrombin in whole blood39, it is possible that
applied thrombin can become gradually inactivated when
coming into contact with subchondral blood. Therefore
contact between thrombin and the polymereblood mixture
should ideally occur within 10 s, which in the absence of
a co-delivery device could be a limiting factor in clinical
practice. By comparison, exposure of TF to whole blood is
expected to further activate TF, which could explain why
TFþ rhVIIa still accelerated implant solidiﬁcation even after
a w60 s delay in pre-loading. Another limitation of our in
vivo study was the use of human clotting factors in a rabbit
model, although pilot ex vivo tests showed that rabbit blood
coagulated more rapidly when exposed to all of the human
clot factors used (unpublished observations). For clinical
applications, human thrombin is preferred over bovine
thrombin, given that some patients can develop antithrom-
bin antibodies after even a one-time exposure to bovine
thrombin43.
Our study was partly motivated by the knowledge that
many clotting factors promote therapeutic effects in wound
repair. Tissue factor was previously shown to stimulate
angiogenesis44 and bone repair in human patients receiving
maxillary bone grafts25. Thrombin promotes cell migration
and proliferation of many cell types implicated in wound
healing of osteochondral defects45e47 and stimulates angio-
genesis48. ChitosaneGP/blood clots demonstrated a longerTAT generation, and sustained levels of PF4, which could
be beneﬁcial to acute repair processes. Platelet factors
such as PF4 are known to elicit innate immune cells49
and since innate immune activation, angiogenesis, and
bone repair have all been identiﬁed in the mechanisms of
repair by chitosan clot implants15,17,19 addition of clotting
factors such as puriﬁed thrombin, recombinant TF or
rhFVIIa have the potential to contribute even further the
quality of hyaline repair elicited by these hybrid implants.
Conclusions
ChitosaneGP/blood mixtures solidiﬁed through coagula-
tion processes involving thrombin generation, ﬁbrin poly-
merization and platelet activation and achieved a clot
tensile strength similar to whole blood clots. Once solidiﬁed,
hybrid clots maintained partial tensile strength in the pres-
ence of tPA. Hybrid clots demonstrate practical advantages
over normal blood clots, as chitosan physically stabilized
the clot from lysis and in addition stabilized platelet factor
4 and TAT against rapid degradation in serum after clotting.
Clotting factors of the extrinsic clotting cascade and throm-
bin can be used to accelerate in situ solidiﬁcation of inject-
able chitosaneGP/blood implants in drilled articular
cartilage lesions in vivo. Clotting factors have the potential
to enhance the practical use, the residency, and therapeutic
activity of polymereblood implants.
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